- Home
- SGMT vs OBIO Comparison
SGMT vs OBIO Comparison
Compare SGMT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMT | OBIO |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.7M | 237.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGMT | OBIO |
|---|---|---|
| Price | $6.33 | $4.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $29.75 | $14.00 |
| AVG Volume (30 Days) | ★ 541.5K | 321.3K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,818,000.00 |
| Revenue This Year | N/A | $36.43 |
| Revenue Next Year | N/A | $2.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $1.73 | $2.20 |
| 52 Week High | $11.41 | $6.30 |
Technical Indicators
Market Signals| Indicator | SGMT | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 52.97 |
| Support Level | $5.95 | $4.19 |
| Resistance Level | $6.58 | $4.69 |
| Average True Range (ATR) | 0.39 | 0.33 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 28.46 | 32.97 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.